Online inquiry

IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6478MR)

This product GTTS-WQ6478MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, CT-P-59(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6478MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5510MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ8129MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA HH1
GTTS-WQ11766MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MK-1308
GTTS-WQ11997MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MM-121
GTTS-WQ4967MR IVTScrip™ mRNA-Anti-GP, c2G4-N(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA c2G4-N
GTTS-WQ1418MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ACA125
GTTS-WQ12694MR IVTScrip™ mRNA-Anti-DLL4, OMP-21M18(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMP-21M18
GTTS-WQ15618MR IVTScrip™ mRNA-Anti-TNFRSF13C, VAY-736(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA VAY-736
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW